DATE CHANGE - October 5-8, 2022 - IWWM-11 Madrid, Spain
The IWWM-11’s primary concern is the health and safety of those involved in our activities. Given the massive and worldwide impact of the COVID-19 crisis, the Workshop Scientific and Chair Committees have decided to reschedule the 11th International Workshop on Waldenstrom’s macroglobulinemia (IWWM-11), in Madrid, Spain, to October 5-8, 2022.
Our sympathy and respect goes out to all involved in fighting the COVID-19 crisis. We urge all of you to stay safe and to regularly visit our special COVID-19 Hematology Hub for the latest updates.
The 11th International Workshop for Waldenstrom's Macroglobulinemia is being held October 5-8, 2022 in Madrid, Spain. The venue chosen for this meeting is one of Madrid’s premier hotels, Westin Palace Madrid, situated in the Las Letras quarter. The hotel nestles in one of the city’s most historic areas linking the city’s most enriching museums, Prado, Reina Sofia and Thyssen-Bornemisza, vibrant parks and gardens, and epicurean eateries. Instructions for registration and check-in will be provided as we get closer to the newly rescheduled dates.
The Workshop’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic system, by promoting targeted research, clinical care methods, education, training, and advocacy for Waldenstrom’s macroglobulinemia. IWWM-11 will continue to support future research by including a Junior Investigator Poster presentation event with short oral presentations. Instructions for Abstract submissions for poster presentations will be announced at a later date..
Read more: DATE CHANGE - October 5-8, 2022 - IWWM-11 Madrid, Spain
Waldenstrom's Macroglobulinemia Clinic
The Waldenstrom's Macroglobulinemia Clinic at the DFCI is devoted to the care of patients with Waldenstrom's Macroglobulinemia and related IgM disorders, including IgM MGUS, Myeloma and Neuropathies.
For more information on the WM Clinic at DFCI, please visit the DFCI Center for Hematologic-Oncology/Waldenstrom's Macroglobulinemia Clinic.
Basic Research
Waldenström’s macroglobulinemia (WM) is a distinct B-cell malignancythat results from the accumulation, predominantly in the bone marrow, of clonally related B type lymphocytes, lymphoplasmacytic cells and plasma cells which secrete a monoclonal IgM protein.1 This condition is considered to correspond to the lymphoplasmacytic lymphoma (LPL) as defined by the World Health Organization classification system.2 Most cases of LPL are WM, with less than 5% of cases made up of IgA, IgG and non-secreting LPL ...
Latest Bing Center News
BTK Inhibitors for the Treatment of Waldenström Macroglobulinemia
In this video, an international panel of experts sat down with Oncology Learning Network to discuss the 3 Bruton’s tyrosine kinase (BTK) inhibitors active in the treatment of Waldenström macroglobulinemia (WM): ibrutinib, acalabrutinib, and zanubrutinib.
ASCO 2020 Virtual Meeting
ASCO (American Society of Clinical Oncologists) will hold their 2020 conference online. As in the past, they provide abstracts online via the conference website. The scientific program will take place May 29 through May 31.
Video from CBS-4 Boston - Dr. Treon discusses COVID-19 / Ibrutinib Trial
Researchers say ibrutinib seems to protect those with COVID-19 from lung damage and respiratory distress. They will now conduct a trial to see if the medication can reduce a patient’s need for a ventilator, improve survival and reduce their time in the hospital.
COVID-19 Information for Our Patients
The Bing Center would like to share this important information with all of our patients and interested parties to help us all manage through this unprecedented crisis in the best and most productive way possible.
Waldenström Macroglobulinemia Specialty Channel
Welcome to the Oncology Learning Network Waldenstrom Macroglobulinemia Specialty Channel. Here you will find articles dedicated to the research and treatment of WM.
Dana-Farber to Test Blood Cancer Drug in COVID-19
Scientists at Dana-Farber have launched a clinical test of a blood-cancer drug in patients that have the COVID-19 virus. The test follows several case reports in which the drug, ibrutinib, appeared to protect against lung damage and respiratory distress caused by the novel virus.
BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress
CAMBRIDGE, Mass. and BEIJING, China, May 14, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical and non-clinical data on BTK inhibitor BRUKINSA™
Understanding Waldenström's Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies
We are excited to announce this new webcast on diagnosis, risk stratification, and current and emerging therapies for Waldenström's Macroglobulinemia (WM).
Watch Dr. Jorge Castillo’s engaging “Ask the Doctor” session
Fifty WMers from the Philly WM Support Group enjoyed a lively, engaging and informative conversation with Dr. Jorge Castillo, Clinical Director of the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute.
Drs. Castillo and Kastritis have joined the IWMF Scientific Advisory Committee
The IWMF is proud to welcome two new members to its Scientific Advisory Committee (SAC) chaired by Dr. Steven Ansell of the Mayo Clinic and Dr. Stephen Treon of the Dana-Farber Cancer Institute. The new members, Dr. Jorge Castillo from Dana-Farber, Boston, USA, and Dr. Efstathios Kastritis of Athens, Greece, were invited to participate because of their expertise in specific research areas identified by the IWMF-LLS Strategic Research Roadmap for WM.